Mark Wigglesworth was awarded his Ph.D in 2001 for work conducted on the forced molecular evolution of G protein-coupled receptors for biotechnological application. This was at the University of Leeds within the laboratory of Professor Findlay. Following this he joined GlaxoSmithKline where he continued working within the field of 7 Transmembrane receptors, concentrating on orphan receptor projects as well as the development and utilization of receptor screening systems. Additionally, remaining within the field of lead optimisation he joined the Sample Management department at the beginning of 2008 to lead a team supporting compound provision to iterative chemistry programmes. In this role has responsibility for solution operations across Europe, has worked to evolve Lead Optimisation processing within GSK and has enjoyed the challenges this has brought.